NEW YORK (GenomeWeb News) – Celera and Medco Health Solutions will collaborate to study whether patients who take a test for a specific gene variant are more likely to adhere to their treatment regimens for lipid-lowering statins.

Celera said today that it will work with Medco to conduct a prospective, randomized, multi-center study to find out if testing for the KIF6 variant can be a predictor for patient adherence.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.